Pemphigus Vulgaris Poised To Attain High Growth of $ 677.99 Million With Top Industry Players: Almirall SA, Biogen Inc., Argenx SE, F. Hoffman-La Roche etc. by 2023

Market Overview

Pemphigus vulgaris is a type of autoimmune disease, and the most common among the pemphigus group diseases. Autoimmune diseases occur when the body’s defense system mistakes organic, naturally occurring substances for foreign bodies and attacks them. This can cause widespread reaction within the body. Autoimmune diseases can be deadly for this reason. Until the discovery of immunosuppressants and corticosteroids, many autoimmune diseases had a much higher rate of mortality than at present.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6870

Pemphigus vulgaris is the most common type of pemphigus disease in the United States and has an incidence of 0.5-3.2 per 100,000 worldwide. It results in painful lesions on the mucous membranes of the body, which exist in the mouth, nose, throat, eyes, lungs, and genitals. Pemphigus vulgaris lesions can also spread to join up with each other, creating much larger lesions that spread across the whole face and make it difficult and painful to swallow.

The pemphigus vulgaris market has grown rapidly in the last few decades, following the discovery of the effectiveness of corticosteroids and immunosuppressants in curbing the disease. Before this discovery, in the 1950s, pemphigus vulgaris had a death rate of almost 75%. The introduction of modern medication and early diagnostic procedures has also had a major impact on the mortality of the disease, thus driving the global pemphigus vulgaris market.

On the other hand, the potential hazards of pemphigus vulgaris medication can be a major restraint against the global pemphigus vulgaris market. While corticosteroids and immunosuppressants are powerful medications that are highly effective in treating pemphigus vulgaris, they are also highly bioactive compounds that can have other effects in the body. This is likely to be a major restraint against the global pemphigus vulgaris market and developing effective medication which does not affect the immune system is likely to be a key research channel for players in the global pemphigus vulgaris market over the forecast period.

Segmentation

The global pemphigus vulgaris market is segmented on the basis of treatment, route of administration, end use, and region. By treatment type, the pemphigus vulgaris market is segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin. Immunosuppressants hold the dominant share in the global pemphigus vulgaris market and are likely to remain the major treatment type over the forecast period due to their high effectiveness. By route of administration, the pemphigus vulgaris market is segmented into intravenous, subcutaneous, and oral. Intravenous administration is the most popular route of administration of pemphigus vulgaris drugs, followed by subcutaneous administration. By end-use, the market is segmented into hospitals and clinics, specialty dermatology clinics, and research and academic laboratories. By region, the pemphigus vulgaris market is segmented into the Americas, Europe, Asia Pacific, and rest of the world. The Americas and Europe hold dominant shares in the global pemphigus vulgaris market and are likely to remain the leading contributors to the global market over the forecast period due to the highly advanced state of the healthcare sector and the high prevalence of pemphigus vulgaris among people of Mediterranean descent.

Competitive Analysis

Leading players in the global pemphigus vulgaris market include Biogen Inc. (U.S.), Novartis AG (Switzerland), F. Hoffman-La Roche (Switzerland), Sanofi (France), Syntimmune (India), Argenx SE (Belgium), Janssen Global Services LLC (U.S.), Pfizer Inc. (U.S.), Almirall SA (Spain), and Principia Biopharma (U.S.).

Browse more details @ https://www.marketresearchfuture.com/reports/pemphigus-vulgaris-market-6870

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.